Physician profile
Stuart Hal Goldstein
NPI 1326032178
$544.28
in general payments reported to CMS, 2019-2025
18 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.31 · 2020: $15.25 · 2021: $45.29 · 2022: $152 · 2023: $80.28 · 2024: $73.26 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $86.80 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $60.27 | 2024-2025 | Voquezna |
| Covidien Lp | $53.66 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.04 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $40.06 | 2024 | Jardiance, Zepbound |
| Novo Nordisk INC | $37.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.13 | 2022 | |
| Glaxosmithkline, LLC. | $18.00 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $17.51 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2023 | Trintellix |
| Amarin Pharma, INC. | $15.25 | 2020 | |
| Esperion Therapeutics, INC. | $14.95 | 2024 | Nexletol |
| Neurocrine Biosciences, INC. | $14.48 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $14.45 | 2021 | |
| Penumbra, INC. | $13.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.